Genotype 1a

TABLE 118: SVR GENOTYPE 1A TREATMENT-EXPERIENCED WITH PRIOR NULL RESPONSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PR48	5.51 (1.70 to 18.80)	69.67 (7.37 to 86.70)
PAR/RIT24 + OMB24 + DAS24 + RBV24		5.94 (1.73 to 20.49)	75.79 (7.26 to 90.80)
T12 PR48 q8		1.12 (0.22 to 4.22)	1.62 (−17.95 to 21.84)
SIM12 PR48		1.85 (0.33 to 7.33)	12.18 (−12.43 to 43.91)
PAR/RIT24 + OMB24 + DAS24 + RBV24	PAR/RIT12 + OMB12 + DAS12 + RBV12	1.06 (0.57 to 2.14)	4.85 (−20.49 to 34.88)
T12 PR48 q8		0.20 (0.06 to 0.46)	−67.40 (−80.70 to −10.76)
SIM12 PR48		0.34 (0.08 to 0.91)	−55.31 (−76.02 to −1.88)
T12 PR48 q8	PAR/RIT24 + OMB24 + DAS24 + RBV24	0.19 (0.05 to 0.49)	−73.47 (−87.39 to −9.36)
SIM12 PR48		0.32 (0.07 to 0.92)	−61.58 (−83.29 to −1.49)
SIM12 PR48	T12 PR48 q8	1.62 (0.70 to 4.34)	10.24 (−3.11 to 32.46)
Random effect model	Residual deviance	12.13 vs. 10 data points	

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
	Deviance information criteria	60.688	
Fixed effect model	Residual deviance	13.75 vs. 10 data points	
	Deviance information criteria	61.415	

CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.